1Francis GS,Benedict C,Johnstone DE,et al.Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure.A substudy of the studies of left ventricular dysfunction(SOLVD)[J].Circulation,1990,82:1724-1729.
2Swedberg K,Eneroth P,Kjekshus J,et al.Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality.CONSENSUS Trial Study Group[J].Circulation,1990,82:1730-1736.
4Brilla CG,Zhou G,Matsubara L.et al.Collagen metabolism in cultured adult rat cardiac fibroblasts:response to angiotensin Ⅱ and aldosterone[J].J Mol Cell Cardiol,1994,26:809-820.
5Robert V,Heymes C,Silvestre JS,et al.Angiotensin AT1 receptor subtype as a cardiac target of aldosterone:role in aldosterone -salt-induced fibrosis[J].Hypertension,1999,33:981-986.
6Sigel AV,Centrella M,Eghbali-Webb M.Regulation of Droliferative response of cardiac fibroblasts by transforming growth factor-betal[J].J Mol Cell Cardiol,1996,28:1921-1929.
7Brown NJ,Kim KS,Chen YQ,et al.Synergistec eftect of adrenal steroids and angiotensin Ⅱ on plasminogen activator inhibitor-1 produetion[J].J Clin Endocrinol Metab,2000,85:336-344.
8Mizuno Y,Yoshimura M,Yasue H,et al.Aldosterone production is activated in failing ventricle in humans[J].Circulation,2001,86:5121-5126.
9Zannad F,Alia F,Dousset B,et al.Limitation of excessive extracellular matrix turnover may contribute to survial benefit of spironolactone therapy in patients with congestive heart failure:insights from the randomized aldactone evaluation study (RALES).Rales Investigators[J].Circulation,2000,102:2700-2706.
3Pitt B. A new HOPE for aldosterone blockade? [J]. Cir- culation, 2004,110 ( 13 ) : 1714-1716. \.
4Pitt B, Zannad F, Remme W J, et al. The effect of spi- ronolactone on morbidity and mortality in patients with se- vere heart failure. Randomized Aldactone Evaluation Study Investigators[ Jl. N Engl J Med, 1999,341 (10) :709 -717.
5Pitt B, Remme W, Zannad F, et al. Eplerenone, a selec- tive aldosterone blocker, in patients with left ventricnlar dysfunction after myocardial infarction[ J ]. N Engl J Med, 2003,348 (14) : 1309-1321.
6Baliga R R, Ranganna P, Pitt B, et al. Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospec- tive analysis[J]. J Card Fail, 2006,12(4):250-256.
